全文获取类型
收费全文 | 23130篇 |
免费 | 1650篇 |
国内免费 | 143篇 |
专业分类
耳鼻咽喉 | 199篇 |
儿科学 | 832篇 |
妇产科学 | 633篇 |
基础医学 | 3085篇 |
口腔科学 | 374篇 |
临床医学 | 2438篇 |
内科学 | 4759篇 |
皮肤病学 | 495篇 |
神经病学 | 2602篇 |
特种医学 | 492篇 |
外科学 | 2050篇 |
综合类 | 150篇 |
一般理论 | 37篇 |
预防医学 | 3035篇 |
眼科学 | 289篇 |
药学 | 1434篇 |
1篇 | |
中国医学 | 39篇 |
肿瘤学 | 1979篇 |
出版年
2024年 | 32篇 |
2023年 | 377篇 |
2022年 | 684篇 |
2021年 | 1198篇 |
2020年 | 752篇 |
2019年 | 989篇 |
2018年 | 1066篇 |
2017年 | 806篇 |
2016年 | 867篇 |
2015年 | 911篇 |
2014年 | 1186篇 |
2013年 | 1427篇 |
2012年 | 2098篇 |
2011年 | 2118篇 |
2010年 | 1095篇 |
2009年 | 923篇 |
2008年 | 1365篇 |
2007年 | 1289篇 |
2006年 | 1199篇 |
2005年 | 1039篇 |
2004年 | 887篇 |
2003年 | 749篇 |
2002年 | 645篇 |
2001年 | 98篇 |
2000年 | 77篇 |
1999年 | 84篇 |
1998年 | 101篇 |
1997年 | 92篇 |
1996年 | 70篇 |
1995年 | 75篇 |
1994年 | 49篇 |
1993年 | 54篇 |
1992年 | 43篇 |
1991年 | 39篇 |
1990年 | 31篇 |
1989年 | 28篇 |
1988年 | 40篇 |
1987年 | 28篇 |
1986年 | 25篇 |
1985年 | 19篇 |
1984年 | 34篇 |
1983年 | 17篇 |
1982年 | 27篇 |
1981年 | 32篇 |
1980年 | 22篇 |
1979年 | 11篇 |
1978年 | 13篇 |
1974年 | 15篇 |
1973年 | 12篇 |
1972年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
Erkens Christiane Scharmanski Sara Heßling Angelika 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2021,64(11):1382-1390
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Seit 1998 erhebt die Bundeszentrale für gesundheitliche Aufklärung (BZgA) im Rahmen ihrer Repräsentativbefragung... 相似文献
92.
Madsen Christina Merete Tvede Bisgaard Sara Kjær Primdahl Jette Christensen Jeanette Reffstrup von Bülow Cecilie 《Journal of occupational rehabilitation》2021,31(4):866-885
Journal of Occupational Rehabilitation - Purpose To present an overview of the evidence of the effect of job loss prevention interventions, aiming to improve work ability and decrease absenteeism... 相似文献
93.
Amyn A. Malik Neel R. Gandhi Timothy L. Lash Lisa M. Cranmer Saad B. Omer Junaid F. Ahmed Sara Siddiqui Farhana Amanullah Aamir J. Khan Salmaan Keshavjee Hamidah Hussain Mercedes C. Becerra 《Emerging infectious diseases》2021,27(3):805
In Karachi, Pakistan, a South Asian megacity with a high prevalence of tuberculosis (TB) and low HIV prevalence, we assessed the effectiveness of fluoroquinolone-based preventive therapy for drug-resistant (DR) TB exposure. During February 2016–March 2017, high-risk household contacts of DR TB patients began a 6-month course of preventive therapy with a fluoroquinolone-based, 2-drug regimen. We assessed effectiveness in this cohort by comparing the rate and risk for TB disease over 2 years to the rates and risks reported in the literature. Of 172 participants, TB occurred in 2 persons over 336 person-years of observation. TB disease incidence rate observed in the cohort was 6.0/1,000 person-years. The incidence rate ratio ranged from 0.29 (95% CI 0.04–1.3) to 0.50 (95% CI 0.06–2.8), with a pooled estimate of 0.35 (95% CI 0.14–0.87). Overall, fluoroquinolone-based preventive therapy for DR TB exposure reduced risk for TB disease by 65%. 相似文献
94.
95.
Elin Vimefall Mattias Persson Sara Olofsson Lars Hultkrantz 《The European journal of health economics》2022,23(2):261-275
The European Journal of Health Economics - This paper compares the value per statistical life (VSL) in the context of suicide prevention to that of prevention of traffic fatalities. We conducted... 相似文献
96.
Kisser Agnes Knieriemen Joschua Fasan Annette Eberle Karolin Hogger Sara Werner Sebastian Taube Tina Rasch Andrej 《The European journal of health economics》2022,23(5):863-878
The European Journal of Health Economics - The transferability of the EU joint clinical assessment (JCA) reports for pharmaceuticals for the German benefit assessment was evaluated by... 相似文献
97.
Olofsson Sara Graln Katarina Hoxer Christina Okhuoya Paul Persson Ulf 《The European journal of health economics》2022,23(6):993-1005
The European Journal of Health Economics - Phenylketonuria (PKU) is a metabolic disorder leading to a deficiency in the metabolism of phenylalanine (Phe). Elevated Phe levels in the blood, tissue... 相似文献
98.
Luigi Gennari Daniela Merlotti Natale Figura Christian Mingiano Maria Beatrice Franci Barbara Lucani Tommaso Picchioni Mario Alessandri Maria Stella Campagna Sara Gonnelli Simone Bianciardi Maria Materozzi Carla Caffarelli Stefano Gonnelli Ranuccio Nuti 《Journal of bone and mineral research》2021,36(1):80-89
Helicobacter pylori (HP) infection is a common and persistent disorder acting as a major cofactor for the development of upper gastrointestinal diseases and several extraintestinal disorders including osteoporosis. However, no prospective study assessed the effects of HP on bone health and fracture risk. We performed a HP screening in a population-based cohort of 1149 adults followed prospectively for up to 11 years. The presence of HP infection was assessed by serologic testing for serum antibodies to HP and the cytotoxin associated gene-A (CagA). The prevalence of HP infection did not differ among individuals with normal bone mineral density (BMD), osteoporosis, and osteopenia. However, HP infection by CagA-positive strains was significantly increased in osteoporotic (30%) and osteopenic (26%) patients respect to subjects with normal BMD (21%). Moreover, anti-CagA antibody levels were significantly and negatively associated with lumbar and femoral BMD. Consistent with these associations, patients affected by CagA-positive strains had a more than fivefold increased risk to sustain a clinical vertebral fracture (HR 5.27; 95% CI, 2.23–12.63; p < .0001) and a double risk to sustain a nonvertebral incident fracture (HR 2.09; 95% CI, 1.27–2.46; p < .005). Reduced estrogen and ghrelin levels, together with an impaired bone turnover balance after the meal were also observed in carriers of CagA-positive HP infection. HP infection by strains expressing CagA may be considered a risk factor for osteoporosis and fractures. Further studies are required to clarify in more detail the underlying pathogenetic mechanisms of this association. © 2020 American Society for Bone and Mineral Research (ASBMR). 相似文献
99.
Kristin M D'Silva Sara Jane Cromer Elaine W Yu Michael Fischer Seoyoung C Kim 《Journal of bone and mineral research》2021,36(1):52-60
Zoledronic acid (ZA) is an effective agent in osteoporosis and malignancy-related bone disease but may be associated with increased risk of atrial fibrillation (AF), although current studies disagree on this risk. To examine the risk of incident AF among patients receiving ZA compared with denosumab in the first year of treatment, we performed a new-user, active comparator cohort study including privately insured Americans between January 1, 2010, and June 30, 2019. Individuals aged ≥50 years without known arrhythmia or advanced kidney disease who initiated ZA were 1:1 propensity score (PS)-matched to individuals initiating denosumab in separate osteoporosis and malignancy cohorts. The primary outcome was incident diagnosis of AF (≥ 1 inpatient or ≥ 2 outpatient diagnostic codes) over 1 year. Secondary outcomes included stroke/transient ischemic attack (TIA) and nonvertebral fracture. In the osteoporosis cohort (n = 16,235 pairs), mean age was 71 years, and 93% were female. There was higher risk of AF with ZA compared with denosumab over 1 year (incidence rate [IR] = 18.6 versus 14.9 per 1000 person-years; hazard ratio [HR] = 1.25; 95% confidence interval [CI] 1.04 to 1.50). In the malignancy cohort (n = 7732 pairs), mean age was 70 years, and 66% were female. There was a numerically higher, albeit not statistically significant, risk of AF with ZA compared with denosumab over 1 year (IR = 46.9 versus 39.0 per 1000 person-years; HR = 1.19; 95% CI 1.00 to 1.43; p = 0.06). No difference in stroke/TIA rates occurred. In the malignancy cohort, ZA was less effective than denosumab at preventing nonvertebral fractures (HR = 1.32; 95% CI 1.01 to 1.74). Compared with denosumab, ZA treatment for osteoporosis and possibly for malignancy-related bone disease is associated with modestly increased risk of incident AF in the first year of treatment. © 2020 American Society for Bone and Mineral Research (ASBMR). 相似文献
100.
Luca Degli Esposti Valentina Perrone Diego Sangiorgi Margherita Andretta Fausto Bartolini Arturo Cavaliere Andrea Ciaccia Stefania Dell'orco Stefano Grego Sara Salzano Loredana Ubertazzo Adriano Vercellone Davide Gatti Angelo Fassio Ombretta Viapiana Maurizio Rossini Giovanni Adami 《Journal of bone and mineral research》2021,36(11):2177-2183
The determinants of the susceptibility to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection and severe coronavirus disease 2019 (COVID-19) manifestations are yet not fully understood. Amino-bisphosphonates (N-BPs) have anti-inflammatory properties and have been shown to reduce the incidence of lower respiratory infections, cardiovascular events, and cancer. We conducted a population-based retrospective observational cohort study with the primary objective of determining if oral N-BPs treatment can play a role in the susceptibility to development of severe COVID-19. Administrative International Classification of Diseases, Ninth Revision, Clinical ModificationI (ICD-9-CM) and anatomical-therapeutic chemical (ATC) code data, representative of Italian population (9% sample of the overall population), were analyzed. Oral N-BPs (mainly alendronate and risedronate) were included in the analysis, zoledronic acid was excluded because of the low number of patients at risk. Incidence of COVID-19 hospitalization was 12.32 (95% confidence interval [CI], 9.61–15.04) and 11.55 (95% CI, 8.91–14.20), of intensive care unit (ICU) utilization because of COVID-19 was 1.25 (95% CI, 0.38–2.11) and 1.42 (95% CI, 0.49–2.36), and of all-cause death was 4.06 (95% CI, 2.50–5.61) and 3.96 (95% CI, 2.41–5.51) for oral N-BPs users and nonusers, respectively. Sensitivity analyses that excluded patients with prevalent vertebral or hip fragility fractures and without concomitant glucocorticoid treatment yielded similar results. In conclusion, we found that the incidence of COVID-19 hospitalization, intensive care unit (ICU) utilization, and COVID-19 potentially related mortality were similar in N-BPs–treated and nontreated subjects. Similar results were found in N-BPs versus other anti-osteoporotic drugs. We provide real-life data on the safety of oral N-BPs in terms of severe COVID-19 risk on a population-based cohort. Our results do not support the hypothesis that oral N-BPs can prevent COVID-19 infection and/or severe COVID-19; however, they do not seem to increase the risk. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). 相似文献